Talarozole-Mediated atRA Accumulation for SURF1 Leigh Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are currently no therapeutic options for Leigh syndrome, a severe neurologic mitochondrial disorder caused by mitochondrial complex IV deficiency, particularly affecting SURF1-dependent Leigh syndrome, which results in selective damage to dopaminergic neurons and leads to intellectual disability and muscle weakness.
Innovation Solution
Talarozole, a cytochrome P450 (CYP) 26 specific inhibitor, is used to increase all-trans-retinoic acid (atRA) concentrations, thereby enhancing mitochondrial biogenesis and improving neuronal growth and connectivity in SURF1-mutant cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If talarozole is used to increase atRA concentrations, then mitochondrial biogenesis is enhanced and neuronal growth is improved, but the complexity of the treatment mechanism increases
Solution Approach 1:
Talarozole acts as an intermediary substance that blocks CYP26 enzyme activity, thereby preventing the degradation of all-trans-retinoic acid (atRA). This intermediary mechanism allows atRA to accumulate to therapeutic levels, enhancing mitochondrial biogenesis and neuronal growth without requiring direct administration of complex mitochondrial therapies.
Solution Approach 2:
The treatment mechanism changes the concentration parameter of atRA by inhibiting its metabolism through CYP26 blockade. This parameter change (increased atRA concentration) directly drives the beneficial effects on mitochondrial function and neuronal development, simplifying the therapeutic approach to a single pharmacological parameter adjustment.
2Object-affected harmful factors
If conventional treatments are avoided for Leigh syndrome, then harmful effects on dopaminergic neurons are reduced, but no therapeutic benefit is achieved
Solution Approach 1:
The invention converts the harmful effect of CYP26-mediated atRA degradation into a beneficial therapeutic mechanism. By blocking this degradation pathway with talarozole, the natural protective role of atRA against dopaminergic neuron damage is enhanced, transforming a metabolic vulnerability into a therapeutic opportunity.
Solution Approach 2:
The treatment leverages the body's endogenous atRA production system. Instead of administering external mitochondrial therapies, the approach allows the body's own atRA to accumulate to protective levels by simply blocking its degradation, enabling the endogenous system to provide its own therapeutic service.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Talarozole demonstrates a dose-dependent improvement in neurite outgrowth capacity and rescues aberrant neuronal branching, reducing lactate release and increasing the number of dopaminergic neurons in SURF1-dependent Leigh syndrome.
Implementation Method 1
talarozole, a cytochrome P450 (CYP) 26 specific inhibitor, increased the effects of atRA on mitochondrial biogenesis markers
Implementation Method 2
retinoic acid has been used to stimulate the retinoid X receptor-alfa (RXRalfa) in cybrid containing a m.3243A>G mutation, ameliorating the respiratory chain defect
Implementation Method 3
increasing atRA concentrations in human liver via CYP26 inhibition may increase mitochondrial biogenesis and fatty acid beta-oxidation
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 2C~2D
AI summary
The present invention relates to talarozole, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease caused by mitochondrial complex IV deficiency, particularly of SURF 1-dependent Leigh syndrome. The present invention further relates to a pharmaceutical composition comprising as an active ingredient talarozole, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for use in the treatment of a disease caused by mitochondrial complex IV deficiency.